Proven survival – how ZOLADEX can benefit your patients

ZOLADEX is the only LHRHA licensed for all stages of hormone-sensitive prostate cancer

ZOLADEX leads the way with proven survival:

As adjuvant therapy
As neoadjuvant therapy
As monotherapy in advanced prostate cancer

AstraZeneca websites

Search

Site map

Information for

This is an AstraZeneca International website for healthcare professionals. The site is not intended for the following audiences who should use the links below:

US Citizens
UK Patients
UK Physicians
Journalists

Please note

Not all indications / uses of ZOLADEX are registered in all countries. Please consult local prescribing information.

Quick links

ProstateLine.com
CASODEX.net

Features

Site services

Printer friendly